Over 6 1/2 years, 182 @entity1 with @entity3052 were treated with one of two combinations of chemotherapy containing @entity2592 and an @entity4349 ( @entity5699 or @entity632 ). Eighty-one @entity1 achieved remission and 79 of them were entered into one of two trials of active immunotherapy. The first trial compared maintenance chemotherapy and i.v. BCG immunotherapy with chemotherapy alone. The results have shown that the group given i.v. BCG survived for a significantly longer time (P = 0.035) than the group treated only with chemotherapy. The i.v. BCG treated group also had a significantly longer survival (P = 0.042) after their first relapse and a higher incidence of subsequent remissions. However, there was no difference in the length of first remissions for the two groups. The second trial compared two different types of active immunotherapy. The results show no significant difference in remission duration or survival after first relapse for 34 @entity1 randomly allocated to treatment with i.v. BCG or irradiated leukaemic blast cells. Sixteen @entity1 relapsed and subsequently 10 @entity1 entered a second remission after reinduction chemotherapy. These @entity1 were distributed evenly between the two immunotherapy groups and this high rate of second remissions is similar to that for the immunotherapy group in the first Cardiff Trial. In the two trials, 21 (62%) of 34 @entity1 receiving immunotherapy entered a second remission after reinduction chemotherapy and six @entity1 achieved third remissions.

Active immunotherapy for the treatment of XXXX : report of two controlled trials.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity4349 :: ('CHEBI:48120', 'Chemical') :: ['anthracycline'] @entity5699 :: ('MESH:D003630', 'Chemical') :: ['daunorubicin'] @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytosine arabinoside'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myelogenous leukaemia']
@entity3052 :: (MESH:D015470,Disease) :: ['acute myelogenous leukaemia']
